Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157430 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von T M Mohiuddin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Medical Faculty, Justus-Liebig-University Giessen, Klinikstr. 33, 35392 Giessen, Germany. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Epithelial Cell Adhesion Molecule, Cell Adhesion Molecules, Antigens, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: university medical center Giessen and Marburg (UKGM).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a clinically and molecularly heterogeneous subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. In this study, tumor specimens from 104 TNBC patients were analyzed to characterize molecular and clinicopathological features and to assess the expression and therapeutic potential of four key surface markers: epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCAM), tissue factor (TF), and trophoblast cell surface antigen (TROP2). Multiplex immunofluorescence (mIF) demonstrated elevated EGFR and TROP2 expression in the majority of samples. Significant positive correlations were observed between EGFR and TF, as well as between TROP2 and both TF and EpCAM. Expression analyses revealed increased EGFR and TF levels with advancing tumor stage, whereas EpCAM expression declined in advanced-stage tumors. TROP2 and TF expression were significantly elevated in higher-grade tumors. Additionally, EGFR and EpCAM levels were significantly higher in patients with elevated Ki-67 indices. Binding specificity assays using single-chain variable fragment (scFv-SNAP) fusion proteins confirmed robust targeting efficacy, particularly for EGFR and TROP2. These findings underscore the therapeutic relevance of EGFR and TROP2 as potential biomarkers and targets in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Medical Faculty, Justus-Liebig-University Giessen, Klinikstr. 33, 35392 Giessen, Germany.
- Department of Gynaecology and Obstetrics, Brandenburg Medical School Theodor Fontane, University Clinic Brandenburg, Hochstraße 29, 14770 Brandenburg an der Havel, Germany.
ORCID-Profile: T M Mohiuddin, Ivo Meinhold-Heerlein
Förderung
- university medical center Giessen and Marburg (UKGM)
Zitieren
APA
Mohiuddin, T. M., Sheng, W., Zhang, C., Al-Rawe, M., Tchaikovski, S., Zeppernick, F., Meinhold-Heerlein, I., & Hussain, A. F. (2025). Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157430
Vancouver
Mohiuddin TM, Sheng W, Zhang C, Al-Rawe M, Tchaikovski S, Zeppernick F, et al. Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157430
BibTeX
@article{Mohiuddin2025,
author = {Mohiuddin, T M and Sheng, Wenjie and Zhang, Chaoyu and Al-Rawe, Marwah and Tchaikovski, Svetlana and Zeppernick, Felix and Meinhold-Heerlein, Ivo and Hussain, Ahmad Fawzi},
title = {Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157430}
}
EUVIMED